Year All2024202320222021202020192018201720162014201320112010 September 2, 2021 Rhythm Pharmaceuticals to Present at Morgan Stanley 19th Annual Global Healthcare Conference August 12, 2021 Rhythm Pharmaceuticals to Present at the 59th Annual ESPE Meeting August 5, 2021 Rhythm Pharmaceuticals to Present at 2021 Canaccord Genuity 41st Annual Growth Conference August 3, 2021 Rhythm Pharmaceuticals Reports Second Quarter 2021 Financial Results August 3, 2021 Rhythm Pharmaceuticals Announces Comprehensive Expansion of Clinical Development Program with Five New Phase 2 and 3 Trials Planned to Evaluate Setmelanotide in Rare Genetic Diseases of Obesity July 29, 2021 Rhythm Pharmaceuticals Announces Senior Leadership Additions July 28, 2021 Rhythm Pharmaceuticals Announces Collaborative Research Agreement with Clinical Registry Investigating Bardet-Biedl Syndrome July 27, 2021 Rhythm Pharmaceuticals to Report Second Quarter 2021 Financial Results on Tuesday, August 3, 2021 July 23, 2021 Rhythm Pharmaceuticals Announces European Commission Authorization of IMCIVREE® (setmelanotide)▼ for the Treatment of Obesity and Control of Hunger Associated with POMC, PCSK1 and LEPR Deficiency July 22, 2021 Rhythm Pharmaceuticals and Medison Pharma Partner to Commercialize IMCIVREE™ (setmelanotide) in Israel
September 2, 2021 Rhythm Pharmaceuticals to Present at Morgan Stanley 19th Annual Global Healthcare Conference
August 5, 2021 Rhythm Pharmaceuticals to Present at 2021 Canaccord Genuity 41st Annual Growth Conference
August 3, 2021 Rhythm Pharmaceuticals Announces Comprehensive Expansion of Clinical Development Program with Five New Phase 2 and 3 Trials Planned to Evaluate Setmelanotide in Rare Genetic Diseases of Obesity
July 28, 2021 Rhythm Pharmaceuticals Announces Collaborative Research Agreement with Clinical Registry Investigating Bardet-Biedl Syndrome
July 27, 2021 Rhythm Pharmaceuticals to Report Second Quarter 2021 Financial Results on Tuesday, August 3, 2021
July 23, 2021 Rhythm Pharmaceuticals Announces European Commission Authorization of IMCIVREE® (setmelanotide)▼ for the Treatment of Obesity and Control of Hunger Associated with POMC, PCSK1 and LEPR Deficiency
July 22, 2021 Rhythm Pharmaceuticals and Medison Pharma Partner to Commercialize IMCIVREE™ (setmelanotide) in Israel
